Clinical trials: Falciparum Malaria, open to volunteers
Malaria, Falciparum
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
- Trial name
- NCT07646353
- Testing
- GSK4425689A SC, GSK4425689A IV
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria (Plasmodium Falciparum), Malaria Incidence
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings
- Trial name
- NCT07903324
- Testing
- Factory-treated lesu, Soaked lesu, Untreated lesu
- Where
- Uganda
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria,Falciparum
Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)
This study will assess the durability of protection of a single immunisation with the Genetically Attenuated Parasite 2 (GA2) against controlled human malaria infection by rechallenging previously immunised and protected…
- Trial name
- NCT06293339
- Testing
- CHMI with 3D7 malaria
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Malaria Vivax, Malaria Falciparum
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria…
- Conditions
- Malaria Vivax, Malaria Falciparum, Plasmodium Vivax, Plasmodium Falciparum
- Trial name
- PvSTATEM (NCT06923592)
- Testing
- PvSeroTAT, Control
- Where
- 2 sites in Ethiopia, Madagascar
- Volunteers
- 19,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
- Trial name
- PLATINUM (NCT05750628)
- Testing
- INE963, KAE609 (Cipargamin), SoC (Coartem)
- Where
- 12 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Malaria (Plasmodium Falciparum)
Malaria CVD 36000; Gates INV090205
In order to control infections, the investigators must first detect them. Biosensor devices may allow early detection and intervention for infectious diseases, helping the investigators to recognize infections early, and allow…
- Trial name
- NCT07558122
- Testing
- PfSPZ Challenge (NF54), Wearable Biosensor Devices
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria,Falciparum
Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.
The investigators believe that to effectively achieve malaria elimination in Rwanda, it is critical to target the human reservoirs of Plasmodium falciparum using local and readily available Artemisia tea.
- Trial name
- NCT05801198
- Testing
- Artemisia afra or Annua 10g oral infusion/tea per day for 14 days
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- King Faisal Hospital Rwanda
Malaria Falciparum
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy…
- Trial name
- LARC-Tu (NCT06862453)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Plasmodium Falciparum Malaria
Mass Vaccine and Drug Administration, Bangladesh
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass…
- Trial name
- MVDA (NCT06068530)
- Testing
- DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
- Where
- 2 sites in Bangladesh
- Volunteers
- 10,000 people
- Sponsor
- University of Oxford
Malaria, Asymptomatic Malaria
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Malaria remains a major cause of illness among school-aged children in sub-Saharan Africa, many of whom carry asymptomatic Plasmodium falciparum infections that may contribute to anemia, inflammation, school absenteeism, and…
- Conditions
- Malaria, Asymptomatic Malaria, Intermittent Preventive Treatment
- Trial name
- Optimal LEAP (NCT07798583)
- Testing
- Monthly DP, Quarterly DP
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Malaria
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria
This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to <5 kg with uncomplicated malaria due to Plasmodium…
- Trial name
- NCT07713602
- Testing
- Coartem® Baby
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
This is a single centre, randomized, placebo-controlled phase 1/2 study comparing two malaria vaccine candidates. The first vaccine candidate PfSPZ-CVac (Plasmodium falciparum sporozoites (PfSPZ) challenge administered with a…
- Trial name
- NCT05441410
- Testing
- Pyronaridine Tetraphosphate, Artesunate Drug Combination, PfSPZ Challenge (NF54), MVA ME-TRAP
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Malaria (Plasmodium Falciparum)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL).
- Trial name
- NCT07559370
- Testing
- Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate
- Where
- Kenya
- Volunteers
- 1,116 people
- Sponsor
- Victoria Biomedical Research Institute
Uncomplicated Plasmodium Falciparum Malaria
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs…
- Trial name
- FD-TACT (NCT05951595)
- Testing
- Artemether-Lumefantrine-Amodiaquine (ALAQ), Artemether-Lumefantrine (AL), Artesunate-Amodiaquine (ASAQ)
- Where
- Rwanda
- Volunteers
- 1,680 people
- Sponsor
- University of Oxford
Malaria, Cerebral
DON in Pediatric Cerebral Malaria
The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria.
- Trial name
- NCT05478720
- Testing
- 6-diazo-5-oxo-L-norleucine (DON)
- Where
- 2 sites in Malawi
- Volunteers
- 152 people
- Sponsor
- Douglas Postels, MD, MS
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors.
- Trial name
- WinMal (NCT07912528)
- Testing
- Spatial emanator outdoor, Spatial emanator indoor
- Where
- Papua New Guinea
- Volunteers
- 4,350 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals